USE OF PHOSPHODIESTERASE 5A INHIBITORS FOR THE TREATMENT OF MUSCULAR DYSTROPHY
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 10, 2016
app pub date -
Apr 21, 2014
filing date -
Apr 19, 2013
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Described herein are methods of treating muscular dystrophy, including Becker's muscular dystrophy and Duchenne muscular dystrophy. The methods comprise administering a phosodiesterase 5A (PDE5A) inhibitor, such as tadalafil, to a subject in need thereof. Administering the PDE5A inhibitor has beneficial effects such as restoring functional sympatholysis, alleviating ischemic insult to dystrophin-deficient muscle membranes, reducing use-dependent muscle injury, and thus can slow muscular dystrophy disease progression.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully